Phreesia, Inc. (NYSE:PHR – Get Free Report) SVP David Linetsky sold 720 shares of Phreesia stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $29.50, for a total transaction of $21,240.00. Following the completion of the transaction, the senior vice president now owns 230,051 shares of the company’s stock, valued at $6,786,504.50. This trade represents a 0.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
David Linetsky also recently made the following trade(s):
- On Wednesday, January 29th, David Linetsky sold 500 shares of Phreesia stock. The shares were sold at an average price of $29.68, for a total value of $14,840.00.
- On Monday, January 27th, David Linetsky sold 11,685 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total value of $321,103.80.
- On Wednesday, December 18th, David Linetsky sold 24 shares of Phreesia stock. The shares were sold at an average price of $25.38, for a total value of $609.12.
- On Monday, December 16th, David Linetsky sold 35 shares of Phreesia stock. The stock was sold at an average price of $24.88, for a total transaction of $870.80.
- On Wednesday, December 11th, David Linetsky sold 11,853 shares of Phreesia stock. The stock was sold at an average price of $24.85, for a total transaction of $294,547.05.
Phreesia Trading Up 0.2 %
Shares of PHR stock opened at $28.98 on Friday. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.90. The firm has a fifty day moving average of $25.82 and a 200-day moving average of $23.46. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74.
Analyst Ratings Changes
Several research analysts recently weighed in on PHR shares. Piper Sandler restated an “overweight” rating and issued a $33.00 price objective (up previously from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Citigroup boosted their target price on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Robert W. Baird decreased their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Truist Financial boosted their price objective on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, JMP Securities reiterated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Thirteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia currently has a consensus rating of “Buy” and an average price target of $31.15.
View Our Latest Analysis on PHR
Institutional Investors Weigh In On Phreesia
Institutional investors have recently bought and sold shares of the company. R Squared Ltd bought a new position in shares of Phreesia during the 4th quarter worth approximately $30,000. BankPlus Trust Department bought a new position in Phreesia in the fourth quarter valued at $34,000. International Assets Investment Management LLC lifted its position in Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after buying an additional 1,395 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of Phreesia during the 4th quarter worth about $76,000. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Phreesia by 154.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 3,442 shares of the company’s stock valued at $89,000 after acquiring an additional 2,090 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Articles
- Five stocks we like better than Phreesia
- NYSE Stocks Give Investors a Variety of Quality Options
- MarketBeat Week in Review – 02/03 – 02/07
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Meta Platforms Continues to Prove Why It’s a Premier Play on AI
- Expert Stock Trading Psychology Tips
- IBM’s AI Bet Pays Off—What’s Next for Investors?
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.